ESC Guidelines: Controlling Dyslipidemia (English Version)

Management of dyslipidemia either targeting primary prevention in apparently healthy individuals or secondary prevention in ASCVD patients should follow a standard plan that assess the risk profile of the patient upon which we decide the treatment target and so choose the appropriate treatment modality.

2021 ESC Guidelines of CVD Prevention
https://www.escardio.org/Guidelines/C...

2019 ESC Guidelines of Dyslipidemia
https://www.escardio.org/Guidelines/C...

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
https://www.ncbi.nlm.nih.gov/pmc/arti...

Trajectories of Non-HDL C Across Midlife: Implications for Cardiovascular Prevention
https://www.ncbi.nlm.nih.gov/pmc/arti...

A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke.
https://pubmed.ncbi.nlm.nih.gov/31738...

Comparison of fasting and non-fasting lipid profiles in a large cohort of patients presenting at a community hospital
https://www.researchgate.net/publicat...

Comparison of Novel Equations for Estimating Low-Density Lipoprotein Cholesterol in Patients Undergoing Coronary Angiography
https://www.ncbi.nlm.nih.gov/pmc/arti...

Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease.
https://pubmed.ncbi.nlm.nih.gov/31216...

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
https://www.nejm.org/doi/full/10.1056...

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
https://www.cochranelibrary.com/centr...

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
https://europepmc.org/article/med/270...

PCSK9 Antibody-based Treatment Strategies for Patients With Statin Intolerance
https://www.ncbi.nlm.nih.gov/pmc/arti...